JP2013513559A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513559A5
JP2013513559A5 JP2012542431A JP2012542431A JP2013513559A5 JP 2013513559 A5 JP2013513559 A5 JP 2013513559A5 JP 2012542431 A JP2012542431 A JP 2012542431A JP 2012542431 A JP2012542431 A JP 2012542431A JP 2013513559 A5 JP2013513559 A5 JP 2013513559A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
pharmaceutical composition
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012542431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513559A (ja
Filing date
Publication date
Priority claimed from EP09075546A external-priority patent/EP2332995A1/en
Application filed filed Critical
Publication of JP2013513559A publication Critical patent/JP2013513559A/ja
Publication of JP2013513559A5 publication Critical patent/JP2013513559A5/ja
Pending legal-status Critical Current

Links

JP2012542431A 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用 Pending JP2013513559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use
EP09075546.3 2009-12-10
PCT/EP2010/067740 WO2011069794A1 (en) 2009-12-10 2010-11-18 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2013513559A JP2013513559A (ja) 2013-04-22
JP2013513559A5 true JP2013513559A5 (https=) 2014-11-06

Family

ID=42091520

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2012542436A Active JP6066474B2 (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542435A Ceased JP2013513364A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542434A Pending JP2013513363A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542433A Pending JP2013513362A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542432A Pending JP2013513361A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542431A Pending JP2013513559A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2015134286A Active JP6199930B2 (ja) 2009-12-10 2015-07-03 中和プロラクチン受容体抗体およびそれらの治療的使用

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2012542436A Active JP6066474B2 (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542435A Ceased JP2013513364A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542434A Pending JP2013513363A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542433A Pending JP2013513362A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用
JP2012542432A Pending JP2013513361A (ja) 2009-12-10 2010-11-18 中和プロラクチン受容体抗体およびそれらの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134286A Active JP6199930B2 (ja) 2009-12-10 2015-07-03 中和プロラクチン受容体抗体およびそれらの治療的使用

Country Status (40)

Country Link
US (6) US20130022606A1 (https=)
EP (13) EP2332995A1 (https=)
JP (7) JP6066474B2 (https=)
KR (2) KR101790366B1 (https=)
CN (6) CN102741291A (https=)
AP (1) AP2012006343A0 (https=)
AR (6) AR079349A1 (https=)
AU (2) AU2010330161B2 (https=)
BR (2) BR112012015852B8 (https=)
CA (6) CA2783678A1 (https=)
CL (2) CL2012001539A1 (https=)
CR (2) CR20120310A (https=)
CU (2) CU20120092A7 (https=)
CY (2) CY1118209T1 (https=)
DK (2) DK2510006T3 (https=)
DO (2) DOP2012000159A (https=)
EA (2) EA028678B1 (https=)
EC (2) ECSP12011965A (https=)
ES (2) ES2603352T3 (https=)
GT (1) GT201200186A (https=)
HR (2) HRP20170016T1 (https=)
HU (2) HUE030143T2 (https=)
IL (2) IL220151A0 (https=)
IN (2) IN2012DN05078A (https=)
LT (2) LT2510002T (https=)
MA (1) MA33888B1 (https=)
ME (1) ME02577B (https=)
MX (2) MX2012006621A (https=)
NZ (2) NZ600512A (https=)
PE (3) PE20121561A1 (https=)
PH (2) PH12012501129A1 (https=)
PL (2) PL2510006T3 (https=)
PT (2) PT2510006T (https=)
RS (2) RS55277B1 (https=)
SG (2) SG181511A1 (https=)
SI (2) SI2510002T1 (https=)
TN (1) TN2012000294A1 (https=)
TW (5) TW201130506A (https=)
WO (6) WO2011069796A1 (https=)
ZA (2) ZA201204213B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
TW201513882A (zh) 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3200823B1 (en) 2014-10-02 2022-11-23 City of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
US11202776B2 (en) * 2017-05-12 2021-12-21 Takeda Pharmaceutical Company Limited Treatment of gastroparesis with triazaspiro[4.5]decanone
US20210128728A1 (en) 2017-07-10 2021-05-06 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN118834297A (zh) * 2023-04-24 2024-10-25 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
WO2004054516A2 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
JP4954709B2 (ja) * 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
AR064801A1 (es) * 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CN102711773A (zh) 2007-05-30 2012-10-03 奥克兰联合服务有限公司 生长激素和相关激素的抑制剂,和其使用方法
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Similar Documents

Publication Publication Date Title
JP2013513559A5 (https=)
US8475790B2 (en) Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
US20240041972A1 (en) Conjugates for immunotherapy
WO2011069795A4 (en) Neutralizing prolactin receptor antibodies and their therapeutic use
AU2004308749B2 (en) CD40 antibody formulation and methods
JP6495899B2 (ja) ホルモン分泌調節剤、及びそれを含む組成物
JP2010110329A5 (https=)
CN111902148A (zh) 治疗肌萎缩和强直性肌营养不良的组合物和方法
JP2020528768A5 (https=)
JP2013534922A5 (https=)
JP2019511222A5 (https=)
RU2015122228A (ru) Терапевтические антитела к CD47
JP2016501892A5 (https=)
JP2018500924A5 (https=)
US20140120088A1 (en) Agents for the treatment of tumors
JP2016534995A5 (https=)
JP2010508847A5 (https=)
US20170202902A1 (en) Conjugates for immunotherapy
JP2014224150A (ja) 対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
WO2015118167A1 (en) Use of mcoln-1 modulators to regulate cell migration
JP2022532229A (ja) 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用
JP2020502198A5 (https=)
JP6814824B2 (ja) アポトーシスを誘導するための組成物及び方法
JP2019535797A5 (https=)
WO2018181648A1 (ja) Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体